• CLSI I/LA35-A

CLSI I/LA35-A

Newborn Screening for Cystic Fibrosis; Approved Guideline, ILA35A2E

Clinical and Laboratory Standards Institute , 11/01/2011

Publisher: CLSI

File Format: PDF

$118.00$236.63


CLSI I/LA35-A: Cystic fibrosis (CF), a common genetic disorder, is due to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Early diagnosis through newborn screening (NBS) benefits patients with CF and is now practiced throughout the United States, Australasia, and most western European countries. This guideline was developed with international consensus and describes comprehensively the laboratory tests for detecting CF risk among newborns as well as recommendations for follow-up care. The document focuses on the use of immunoreactive trypsinogen (IRT) assays and the detection of specific CFTR mutations with the IRT/deoxyribonucleic acid screening strategy. Special attention is given to CFTR mutations in geographically and ethnically diverse populations. A core panel of CFTR mutations is recommended with guidance included on its potential expansion. The intended target audience includes NBS laboratory and program personnel, regulatory agencies, CF center personnel, neonatologists, primary care providers, organizations responsible for networks of CF centers, and a variety of public health policy makers.

CLSI I/LA35-A History

CLSI NBS05

CLSI NBS05

$90.00 $180.00

CLSI I/LA35-A

CLSI I/LA35-A

$118.00 $236.63

CLSI NBS05-A

CLSI NBS05-A

$90.00 $180.00

More CLSI Standards PDF

CSA ANSI Z21.5.2-2013/CSA 7.2-2013
CSA C22.2 NO. 188-13

CSA C22.2 NO. 188-13

$75.00 $151.45

CSA B52-13

CSA B52-13

$108.00 $216.00

CSA Z305.13:13 (R2020)

CSA Z305.13:13 (R2020)

$44.00 $88.00